

# Building Bridges: Strengthening the Industrial Radiopharmaceutical Ecosystem in Oslo



Time	Session	Speaker
08:15-09:00	<b>Registration and mingling</b>	OITL
09:00-09:10	<b>Welcome by OITL – Focus of the seminar</b>	Thor Audun Saga, CEO, Norwegian Medical Cyclotron Center
09:10-11:00	<b>Status of the Preclinical Radiopharmaceutical Development - Industry Partners in Different Stages of Development</b>	Industry
09:10-09:20	GE HealthCare FASTlab™ — Automated, GMP Ready Synthesis of Established and Emerging Molecular Imaging Tracers	Dr. Dag Erlend Olberg, Senior Radiochemist, GE HealthCare
09:20-09:30	Preclinical Development of <sup>18</sup> F-labelled CD8 PET tracers as an Imaging Immuno Diagnostic Biomarker	Dr. Matilde Forni, Senior Nonclinical Scientist, GE HealthCare
09:30-09:45	The Development of ARAspheres (actinium-225-RGD-alginate nanoparticles) for Radioligand Therapy of Glioblastoma	Dr. Michael Dornish, Chief Scientific Officer, Blue Wave Therapeutics AS
09:45-10:00	From Stone to Cancer Therapy	Dr. Sindre Hasfjell, Chief Technical Officer, Thor Medical
10:00-10:15	Building the Next Generation Radioligand Therapy (RLT) Platform	Erlend E. Myrnes, CMC Development Director, Actithera Norway AS
10:15-10:30	The Establishment and Operation of a GMP Manufacturing Plant for a Radiopharmaceutical IMP	Kristine Lofthus, Chief Production Officer, Oncoinvent AS
10:30-10:45	NODE101: A Nanoparticle-Delivered Alpha-Emitting Radiotherapeutic for Locoregional Cancer Therapy	Dr. Tor Espen Stav-Noraas, Co-founder, Node Pharma AS
10:45-11:00	Developing the Next Generation of Targeted Radionuclide Therapy for the Benefit of Cancer Patients	Dr. Jenny Karlsson, Senior Director, Targeted Radiopharmaceuticals, Bayer AS
11:00-11:15	<b>Break</b>	
11:15-12:15	<b>Strengthening Preclinical Infrastructure for Translational Radiopharmacy</b>	
11:15-11:25	Comparative Medicine Infrastructure at IMB, UiO: Enabling Preclinical and Translational Research	Erle Linnea Fevåg, Administrative Manager, Department of comparative medicine, UiO
11:25-11:45	Connecting Discovery to Clinic: OITL's Role in Oslo's Translational Radiopharma Ecosystem.	Dr. Bent Wilhelm Schoultz, R&D director; Christoffer Wikborg, Operational Director, Norwegian Medical Cyclotron Center

# Building Bridges: Strengthening the Industrial Radiopharmaceutical Ecosystem in Oslo



11:45-12:00	Development of Novel Targeted Radiation Therapeutics at Nuclithera	Dr. Ada Repetto-Llamazares, Chief Scientific Officer, NucliThera AS
12:00-12:15	Agilera's Contribution to the Norwegian Ecosystem as a CDMO	Bente Tange Harbø, Sector director, Radiopharmaceutical R&D, Agilera Pharma AS
<b>12:15-13:15</b>	<b>Lunch</b>	
<b>13:15-13:45</b>	<b>Panel Discussion - Industry Aspirations: Preclinical Dosimetry and Clinical Translation</b>	<p><b>Dr. Caroline Stokke</b>, Associate Professor, Department of Physics and Computational Radiology, University of Oslo.</p> <p><b>Dr. Ada Repetto-Llamazares</b>, Chief Scientific Officer, NucliThera AS</p> <p><b>Dr. Frans Valentijn Suurs</b>, Principal Scientist, Bayer AS</p> <p><b>PD Dr. Felix Gremse</b>, Founder and CEO of Gremse-IT GmbH</p> <p><b>Dr. Jessica Lage Fernández</b>, Researcher, NMS (Moderator)</p>
13:45-14:00	Talent Formation – Introduction to NNRC	Dr. Sunniva Siem, Professor, Department of Physics, University of Oslo
14:00-14:15	Facilitators in the Radiopharmaceutical Ecosystem in Norway	Sofia Lindén, Oslo Cancer Cluster
<b>14:15-14:45</b>	<b>Preclinical-to-Clinical Translation</b>	
14:15-14:30	The Future of Radiopharmaceuticals: Alpha Radioligand Therapy with Pb-212	Dr. Tanja Aarvak, Director Program Management, Artbio AS
14:30-14:45	Prospects and Challenges of Preclinical Research and Development for Targeted Alpha Radiotherapy	Dr. Asta Juzeniene, Associate Professor, Biophysics and Medical Physics, University of Oslo
<b>14:45-15:00</b>	<b>Break</b>	
<b>15:00-15:30</b>	<b>Panel Discussion - Overcoming Preclinical Bottlenecks in Radiopharmaceutical Development</b>	<p><b>Dr. Asta Juzeniene</b>, Associate Professor, Department of Physics, University of Oslo</p> <p><b>Dr. Bent Wilhelm Schoultz</b>, R&amp;D director, NMS</p> <p><b>Dr. Matilde Forni</b>, Senior Nonclinical Scientist, GE HealthCare</p> <p><b>Dr. Michael Dornish</b>, Chief Scientific Officer, Blue Wave Therapeutics AS</p> <p><b>Dr. Marion Masitsa Malenge</b>, Director RLT discovery and Preclinical Sciences, Actithera Norway AS,</p> <p><b>Dr. Syed Nuruddin</b>, Associate Director Preclinical Research, (Moderator)</p>

# Building Bridges: Strengthening the Industrial Radiopharmaceutical Ecosystem in Oslo



---

<b>15:30-16:20</b>	<b>Sponsors Presentations</b>	
15:30-15:40	Convenience and Reliability with Hidex AMG Automated Gamma Counter for Biodistribution studies	Sari Viljanen; Product line manager, Nuclear medicine at Hidex Oy
15:40-15:50	Alpha Emitters Imaging, Dosimetry or Workflows for Evaluating New Compounds	BIOEMTECH
15:50-16:00	MR SOLUTIONS GROUP - Redefining Preclinical Imaging	Angela Mega-Camacho, Applications Team Leader & Sales Support in MR SOLUTIONS GROUP
16:00-16:10	Accelerating Candidate Selection and Target Validation with AI-Assisted Quantitative Imaging	PD Dr. Felix Gremse, Founder and CEO of Gremse-IT GmbH
16:10-16:20	Radiopharmacy from discipline to societal impact	Carl Henrik Görbitz, Director, UiO:Life Science
<b>16:20-16:30</b>	<b>Closing remarks</b>	NMS/OITL and Oslo Cancer Cluster
<b>16:30-18:00</b>	<b>Pizza &amp; social networking</b>	OITL

---